Press Releases


Lilly's Taltz® (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)

June 1, 2020

Tags |  Product

- Taltz is now approved to treat patients across the full axSpA spectrum, including ankylosing spondylitis (AS), also known as radiographic axSpA, and nr-axSpA - INDIANAPOLIS , June 1, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the U.S.




Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans

June 1, 2020

Tags |  Product

- First patients have been dosed in a Phase 1 study of LY-CoV555, the lead antibody from Lilly's collaboration with AbCellera   - The placebo-controlled study will assess safety and tolerability in patients hospitalized with COVID-19 with results anticipated by the end of June   - Should Phase 1




Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

May 29, 2020

Tags |  Product

CYRAMZA, in combination with erlotinib, now approved for the treatment of people with untreated metastatic non-small cell lung cancer (NSCLC) with certain activating EGFR mutations, based on the positive global Phase 3 RELAY study   CYRAMZA regimen reduced the risk of disease progression or death




Lilly Receives U.S. FDA Approval of TAUVID™ (flortaucipir F 18 injection) for Use in Patients Being Evaluated for Alzheimer's Disease

May 28, 2020

Tags |  Product

The first and only approved diagnostic agent to image tau neurofibrillary tangles in the brain INDIANAPOLIS , May 28, 2020 /PRNewswire/ -- TAUVID ™ , a radioactive diagnostic agent, has been approved by the FDA for positron emission tomography (PET) imaging of the brain to estimate the density and




Statement from Lilly Chairman and CEO Dave Ricks on New Part D Senior Savings Model

May 26, 2020

Tags |  Product

INDIANAPOLIS , May 26, 2020 /PRNewswire/ -- President Donald J. Trump and Seema Verma , Administrator for the Centers for Medicare & Medicaid Services , today announced details of the new Part D Senior Savings Model that will allow people in the Medicare Part D program to buy their monthly




Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance's® effects following an acute myocardial infarction

May 26, 2020

Tags |  Product

- Ischemic heart disease, including myocardial infarction, is the leading cause of death in the U.S. - EMPACT-MI is the first trial in the SGLT2 inhibitor class to investigate the prevention of heart failure after acute myocardial infarction in adults with and without diabetes - The trial is part




Emgality® Shows Improvement in Work Productivity and Health and Well-Being Between Attacks in Patients with Migraine and a History of Preventive Treatment Failure

May 26, 2020

Tags |  Product

INDIANAPOLIS , May 26, 2020 /PRNewswire/ -- Emgality ® (galcanezumab-gnlm) significantly improved work productivity and reduced interictal burden, defined as health and well-being between migraine attacks, in an analysis of the 3-month double-blind period of the CONQUER study, which included




Results of GERAS-US Study Demonstrate Societal Cost Burden for Patients and Caregivers During Early Stages of Alzheimer's Disease

May 19, 2020

Tags |  Product

Early Alzheimer's disease poses financial burdens on patients, caregivers and society INDIANAPOLIS , May 19, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) announced baseline results from the GERAS-US Study examining the societal costs associated with mild cognitive impairment (MCI), mild




Lilly Oncology Showcases Innovation in Cancer Research at ASCO 2020

May 13, 2020

Tags |  Product

Latest Phase 1/2 LIBRETTO-001 registrational trial data examining Retevmo™ (selpercatinib) demonstrate commitment to advancing precision medicines for hard-to-treat tumor types Data on Verzenio® (abemaciclib) continue to reinforce the therapy's role in treating people with aggressive HR+, HER2-




Lilly Receives U.S. FDA Approval for Retevmo™ (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and Thyroid Cancers

May 8, 2020

Tags |  Product

- Approved for metastatic RET fusion-positive NSCLC, advanced or metastatic RET-mutant MTC and advanced or metastatic RET fusion-positive thyroid cancer - Accelerated approval based on data from LIBRETTO-001 Phase 1/2, largest trial ever reported in patients with RET-driven cancers - Registrational